Rudolf Hanko – CEO, Siegfried, Switzerland
Developing manufacturing capacity for as yet unapproved drugs can create huge risk on innovators’ balance sheets, risk which can be mitigated by working instead with a competent CMO – a…
Understanding the mechanisms of disease
The Friedrich Miescher Institute is devoted to fundamental biomedical research aimed at understanding the basic molecular mechanisms of health and disease. We communicate and patent our findings to enable their translation into medical application.
The FMI focuses on the fields of
» Epigenetics
» Quantitative Biology
» Neurobiology
In these fields, the FMI has gained international recognition as a center of excellence in innovative biomedical research.
Training young scientists
The Friedrich Miescher Institute contributes to the training of graduate students and postdoctoral fellows. Through its PhD program, which was established as early as 1970, the FMI attracts top international students. The FMI is affiliated with the University of Basel, where most of the graduate students are enrolled and where it contributes to the teaching program. Many FMI alumni have gone on to pursue successful careers in Novartis, in other pharmaceutical companies, or in academic research.
Contact
Friedrich Miescher Institute for Biomedical Research
Maulbeerstrasse 66
4058 Basel
Switzerland
Tel.: +41 61 697 66 51
Developing manufacturing capacity for as yet unapproved drugs can create huge risk on innovators’ balance sheets, risk which can be mitigated by working instead with a competent CMO – a…
Specializing in ultra-rare diseases, Alexion targets patient populations of less than 20 patients per million. Christophe Bourdon discusses Alexion’s progress towards developing access for patients across the EMEA region. …
It is tempting to characterize Switzerland’s global pharma and life science hotspots as beginning and ending with Basel – home of industry giants Roche and Novartis. However, Zurich, Geneva, and…
Dr. Andrea Michael Meyer, general manager of Sanofi Genzyme Switzerland, reveals how the Swiss business has been experiencing year-on-year double-digit growth; how rare diseases was the foundation of Sanofi Genzyme´s…
Bernhard Neidhart, head of Office for Economy and Labor in Zug, introduces us to the Canton of Zug and explains how the region became a hotspot for pharma. To…
For the eighth year in a row the World Economic Forum has ranked Switzerland first in both global competitiveness and in innovation; economiesuisse CEO Monika Rühl discusses the main issues…
Michelle Lock describes the positive challenges that come with expanding a biopharmaceutical business that possesses a well-regarded pipeline, and that continuously launches products across the Alpine region. She highlights the…
An increasing number of pharma MNCs are looking towards Switzerland for their European base. Despite high costs compared to elsewhere in Europe, Switzerland’s infrastructure, location, and R&D ecosystem make it…
An increasing number of pharma MNCs are looking towards Switzerland for their European base. Despite high costs compared to elsewhere in Europe, Switzerland’s infrastructure, location, and R&D ecosystem make it…
Dr. André T. Dahinden, General Manager of Amgen Switzerland, talks about their four cutting-edge products that will help drive future growth, reveals how being innovative includes partnering with payers for…
Michael Cobas Meyer of Eli Lilly Switzerland reveals how these are very exciting times for the company, particularly given an extremely rich pipeline in the areas of diabetes, oncology and…
Walter P. Hölzle, president of vips, discusses the current priorities of the association, the importance of innovation, and the challenges of the current pricing system. While growth is close to…
See our Cookie Privacy Policy Here
